[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-participants":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,144,0,25,[9,48,85,116,135,156,181,200,220,240,264,281,307,327,346,370,390,419,438,465,483,509,530,552,573],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652901","phase-1-a-study-to-evaluate-the-drug-levels-absolute-bioavailability-safety-tolerability-and-immunogenicity-of-single-dose-of-bms-986446-in-healthy-adults-after-single-dose-administration-and-participants-with-early-alzheimers-disease-after-multiple-dose-administration-100652901",false,"NCT07780383","A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration","A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.","Inclusion Criteria\n\n* Participants must have a BMI of 18.0 to 35.0 kg\u002Fm2.\n* For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.\n* For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.\n* For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).\n* For Part C: Participants must have evidence of positive plasma pTau217.\n\nExclusion Criteria\n\n* For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.\n* For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.\n* For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.\n* For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","80 Years",{"count":22,"type":23},84,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration",[29,30],"Alzheimer's Disease","Healthy Participants",[30,32,33,34,35],"Early Alzheimer's Disease","BMS-986446","Subcutaneous Administration","IV administration","NOT_YET_RECRUITING","2026-08-19",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":39,"type":23},{"date":43,"type":23},"2027-06-17",{"name":45,"class":46},"Bristol-Myers Squibb","INDUSTRY",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":47},"100652602","satiety-microbiome-appetite-regulation-and-tracking-energy-across-targeted-snacks-acute-postprandial-study-100652602","NCT07776418","Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Acute Postprandial Study","The ZOE SMART EATS (Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks) Acute Postprandial Study: Investigating the Acute Effects of a High-fibre Plant-based Snack Bar on Subjective Postprandial Hunger, Energy Intake and Eating Behaviour in Healthy UK Adults.","SMARTEATS-PP","Inclusion Criteria:\n\n* Willing and able to follow the study protocol\n* Willing and able to provide informed consent\n* Regular consumption of snacks (≥2 per day)\n* Fibre intake \\\u003C20 g\u002Fd\n* Living in the UK\n\nExclusion Criteria:\n\n* Have BMI of less than 18.5 kg\u002Fm² or more than 40 kg\u002Fm²\n* Have an allergy or intolerance to ingredients in the intervention or control snack bars (including inulin) or cannot eat the food products safely and comfortably for any reason\n* Have a personal medical history of inflammatory bowel disease, coeliac disease, Crohn's disease, irritable bowel syndrome, chronic constipation, or chronic diarrhoea\n* Have started a new supplement in the past month, or are unwilling to maintain current supplement use throughout the study\n* Previously purchased any ZOE products (including Daily30, ZOE gut health bar or ZOE app membership).\n* Have taken any medication or product that may modify the measured study outcomes, in the past 3 months (including but not limited to: fibre supplements, antibiotics, non-topical steroids or other immunosuppressive medicines, probiotics or prebiotics, metformin, GLP-1 receptor agonists, lipid-lowering medications such as fibrates, statins, PCSK9 inhibitors, non-steroidal anti-inflammatory drugs)\n* Have used opiate pain medication or a proton pump inhibitor for 8 or more consecutive days during the past 3 months\n* Have experienced a heart attack, stroke or major surgery in the last 2 months\n* Have received treatment for cancer in the last 3 months\n* Are currently pregnant, breastfeeding or planning a pregnancy\n* Are diagnosed with an eating disorder, type 1 diabetes mellitus or type 2 diabetes mellitus","35 Years","65 Years",{"count":59,"type":23},54,[61],"NA","The goal of this clinical trial is to learn how eating different snack foods affects acute hunger, energy intake and eating behaviour in healthy adults. The study will be conducted remotely over 5 days.\n\nThe main questions it aims to answer are:\n\n1. Does eating a snack bar intervention change how hungry participants feel later in the same day?\n2. Does eating a snack bar intervention change participants' energy intake, nutrient intake and eating behaviour on the same day?\n3. Does eating a snack bar intervention change participants mood, energy levels and alertness later in the same day?\n\nResearchers will compare an intervention snack bar to a control snack bar to see if the intervention improves hunger, energy intake, eating behaviour, and other subjective measures.\n\nParticipants will:\n\n* Eat 2 snack bars for breakfast on 2 separate days, with 2 days in between\n* Not eat anything after 9pm the night before each test day\n* Fill out short online surveys (under 5 minutes) before breakfast and at set times over the next 3 hours\n* Not eat for 3 hours after breakfast\n* Write down everything they eat that day",[30,64,65,66,67],"Healthy Adult Subject","Healthy Subjects","Healthy Adult Volunteer","Healthy Adult Participants",[69,70,71,72,73,74,75],"Snacks","Snack foods","Dietary intervention","Hunger","Health","Wellbeing","Nutrition study",{"date":77,"type":40},"2026-08-20",{"date":79,"type":23},"2026-08-14",{"date":81,"type":23},"2026-10",{"name":83,"class":84},"Zoe Global Limited","OTHER",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100648496","phase-1-a-study-to-investigate-the-relative-bioavailability-and-safety-of-different-oral-formulations-of-elecoglipron-in-healthy-participants-100648496","NCT07723833","A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","Inclusion Criteria:\n\n* Healthy participants with suitable veins for cannulation or repeated venipuncture.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.\n* Have a body mass index between 18.5 and 30 kg\u002Fm2 inclusive and weigh at least 50 kg.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History of acute pancreatitis.\n* History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma.\n* Participants who have previously received elecoglipron within the last 3 months.","55 Years",{"count":94,"type":23},152,[26],"The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.",[30],[99,100,101,102,103,104,105,106],"Glucagon-like peptide receptor agonist (GLP-1RA)","Type 2 Diabetes Mellitus (T2DM)","Glucose Metabolism Disorders","Metabolic Diseases","Obesity management","Pharmacokinetics","Relative bioavailability","Obesity and Related Co-morbidities","RECRUITING",{"date":77,"type":40},{"date":110,"type":40},"2026-07-27",{"date":112,"type":23},"2026-11-18",{"name":114,"class":46},"AstraZeneca",2,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100616021","phase-1-a-study-to-evaluate-single-and-multiple-doses-of-tlc-1180-in-healthy-subjects-100616021","NCT07300189","A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects","A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of TLC-1180 in Healthy Subjects","Inclusion Criteria:\n\n* Non-smoking, healthy male or female subject between 18 and 55 years of age, inclusive\n* Body mass index from 19 to 35 kg\u002Fm2, inclusive\n* Estimated glomerular filtration rate ≥ 80 mL\u002Fmin\n* Normal liver biochemistry tests\n* Screening laboratory evaluations (hematology, chemistry, and urinalysis) must fall within the normal range of the local laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance\n* Subject must have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that are considered clinically insignificant by the investigator\n* Females of childbearing potential must have a negative pregnancy test at Screening and clinic admission\n* Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception\n* Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs\n\nExclusion Criteria:\n\n* Pregnant or lactating subjects\n* Subjects who have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with the subject's treatment, assessment, or compliance with the protocol\n* Subjects who have received any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to study drug dosing\n* Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety\n* Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety\n* A positive test result for human immunodeficiency virus (HIV-1) antibody, hepatitis B (HBV) surface antigen, or hepatitis C (HCV) antibody\n* Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen (paracetamol), ibuprofen, and\u002For hormonal contraceptive medications\n* Subjects who have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to Screening or expected to receive these agents during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)\n* Medical history of serious skin disease in the opinion of the investigator, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria\n* Medical history of drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)\n* Presence or history of cardiovascular disease, including significant cardiovascular disease (including a history of myocardial infarction based on ECG and\u002For clinical history), history of cardiac conduction abnormalities (including any history of ventricular tachycardia), congestive heart failure, cardiomyopathy with left ventricular ejection fraction \\\u003C 40%, a family history of Long QT Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years\n* Syncope, palpitations, or unexplained dizziness\n* Implanted defibrillator or pacemaker\n* Medical history of liver disease, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency)\n* History of rhabdomyolysis\n* Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions\n* History of medical or surgical treatment that permanently alters intestinal absorption (e.g., gastric or intestinal surgery)\n* Subjects who have received vaccination for COVID-19 within 14 days of Admission\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":124,"type":23},332,[26],"This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.",[30],{"date":39,"type":40},{"date":130,"type":40},"2025-10-20",{"date":132,"type":23},"2028-05-01",{"name":134,"class":46},"OrsoBio, Inc",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":47},"100651127","phase-1-a-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-dnl921-in-healthy-participants-and-participants-with-alzheimers-disease-100651127","NCT07758595","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease","A Phase 1\u002F1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease","Key Inclusion Criteria (Healthy Participants):\n\n* Are male or female of non-childbearing potential and are aged 18 through 60 years at the time of screening\n* Have a BMI of 18 through 32 kg\u002Fm2 and a body weight of at least 50 kg\n* For female participants: Are of non-childbearing potential\n* For male participants: Are surgically sterile by bilateral orchidectomy, or are abstinent, or agree to use two acceptable forms of contraception\n\nKey Exclusion Criteria (Healthy Participants):\n\n* Have any history of clinically significant neurological, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematological, immunological, or allergic disease, or other major disorders\n* Have a positive serum pregnancy test or are currently lactating or breastfeeding\n* Have been hospitalized during the 4 weeks prior to screening\n\nKey Inclusion Criteria (Participants with AD):\n\n* Are male or female of non-childbearing potential and aged 50 to 75 years at the time of screening\n* Have a BMI between 18 and 32 kg\u002Fm2 and a body weight of at least 45 kg\n* Have a diagnosis of probable mild to moderate AD dementia based on NIA AA 2011 criteria, including amnestic or nonamnestic presentation at screening or prodromal AD (consistent with the NIA-AA diagnostic criteria and guidelines for mild cognitive impairment due to AD)\n* Have supportive evidence of AD pathology by the following:\n\n  * Plasma ptau217\u002FAbeta42 positive\n  * Positive amyloid PET scan\n* For female participants: Are of non-childbearing potential\n* For male participants: Are surgically sterile by bilateral orchidectomy, or are abstinent, or agree to use two acceptable forms of contraception\n\nKey Exclusion Criteria (Participants with AD):\n\n* Have other clinically significant neurological or cognitive disorders affecting the CNS, as determined by the investigator, other than AD\n* Have specific psychiatric conditions\n* Have any history of unstable or poorly controlled endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, hematological, or other significant medical condition that, in the opinion of the investigator, may interfere with the completion or interpretation of study assessment\n* Have had a malignancy within 5 years before screening, except fully resected basal cell carcinoma or other malignancies treated with curative intent (such as prostate cancer) at low risk of recurrence\n* Have a positive serum pregnancy test or are currently lactating or breastfeeding\n* Have been hospitalized during the 4 weeks prior to screening\n* Have had previous anti-amyloid or anti-tau immunotherapy (including active immunization) or have participated in experimental gene therapy or cell therapy at any time","75 Years",{"count":144,"type":23},178,[26],"This is a Phase 1\u002F1b, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL921 in healthy participants and participants with Alzheimer's disease (AD). The principal aim of this study is to obtain safety and tolerability data. This information, together with PK and PD data, will inform dose selection and design of future studies.",[29,30],"2026-08-18",{"date":77,"type":40},{"date":151,"type":40},"2026-08-07",{"date":153,"type":23},"2030-04",{"name":155,"class":46},"Denali Therapeutics Inc.",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":163,"minAge":56,"maxAge":142,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":115},"100593992","phase-1-a-study-to-investigate-the-effect-of-azd6234-azd9550-and-a-combination-of-azd9550-and-azd6234-on-pharmacokinetics-of-combined-oral-contraceptive-ethinyl-estradiollevonorgestrel-in-healthy-female-participants-living-with-overweight-or-obesity-100593992","NCT07013643","A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol\u002FLevonorgestrel in Healthy Female Participants Living With Overweight or Obesity","An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol\u002FLevonorgestrel in Healthy Female Participants Living With Overweight or Obesity","Inclusion Criteria:\n\n* All participants must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.\n\n  o Hormonal contraceptives and estrogen-containing hormonal methods of birth control are not permitted due to potential effect and influence on the results using a CoC assessment.\n* Females of non-childbearing potential must be confirmed at the Screening Visit.\n* Have a Body Mass Index (BMI) between 25 and 40 kg\u002Fm2, both inclusive and weigh at least 60 kg for Cohorts 1, 2, and 3 and a BMI of \\> 30 kg\u002Fm2 for Cohort 4.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder (gastroparesis, deep vein thrombosis, venous thromboembolism, previous surgery of the upper gastrointestinal tract, cardiovascular disease, neuromuscular or neurogenic disease, severe vitamin D deficiency (cohort 1, cohort 2 and cohort 4), type I or type II diabetes mellitus, glycated hemoglobin (HbA1c) ≥ 6.5% at screening, history of neoplastic disease (cohort 2, cohort 3 and cohort 4), basal calcitonin level \\>50 ng\u002FL (50 pg\u002FL) at screening (cohort 2, cohort 3 and cohort 4), history of acute or chronic pancreatitis or pancreatic amylase or lipase \\>2×ULN at screening (cohort 2, cohort 3 and cohort 4), prior history of cholecystectomy or untreated cholelithiasis and personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2) (cohort 2, cohort 3 and cohort 4).\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma.\n* Any laboratory values with deviations or clinically important abnormalities in clinical chemistry, hematology, or urinalysis.\n* Any positive result on screening for serum Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) or Human immunodeficiency virus (HIV).\n* Abnormal vital signs.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiogram (ECG), at screening.\n* Current smokers or those who have smoked or used nicotine products.\n* Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity.\n* Statin treatment within 4 weeks prior to the start of study treatment.\n* Current use of estrogen-containing products.","FEMALE",{"count":165,"type":23},50,[26],"This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)\u002Flevonorgestrel (LEVO) in healthy female participants with obesity.",[30],[170,171,172,104,173],"Obesity","Overweight","Oral contraceptives","Drug Interaction","2026-08-17",{"date":148,"type":40},{"date":177,"type":40},"2025-06-04",{"date":179,"type":23},"2027-07-09",{"name":114,"class":46},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100652222","phase-1-a-single-ascending-dose-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-the-effect-of-food-of-syh2056-in-healthy-subjects-100652222","NCT07771777","A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food of SYH2056 in Healthy Subjects","A Randomized, Double-Blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of SYH2056 Tablets in Healthy Subjects","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be enrolled in this study:\n\n1. Age from 18 to 55 years (inclusive).\n2. Male or female, with the proportion of either sex being no less than 1\u002F3.\n3. Weight ≥45.0 kg (females) or ≥50.0 kg (males), and body mass index (BMI) within the range of 18.0 to 26.0 kg\u002Fm2 (inclusive).\n4. Results of vital signs, physical examination, 12-lead ECG, laboratory tests, chest X-ray, B-mode ultrasound (liver, gallbladder, spleen, pancreas, kidneys), thyroid function test, etc., are normal or abnormal but not clinically significant as judged by the investigator.\n5. The participate and their partner agree to use effective non-hormonal contraceptive methods (e.g., condom, inert intrauterine device, female barrier methods \\[cervical cap or diaphragm with spermicide\\], vaginal ring, etc.) from signing the ICF until 3 months after the last dose, or have undergone permanent sterilization (e.g., bilateral tubal ligation, vasectomy, etc.). The participate has no plans to donate sperm or eggs from signing the ICF until 3 months after the end of the study.\n6. Participates must able to read and understand the written informed consent containing study-related information, fully understand the study content, procedures, and possible adverse reactions, voluntarily participate in the clinical study, sign the written ICF, and comply with the study procedures.\n\nExclusion Criteria:\n\nA participate will not be eligible for inclusion in this study if any of the following criteria apply:\n\n1. Participates with history of clinically significant neurological, psychiatric, pulmonary, endocrine, hematological, musculoskeletal, gastrointestinal, cardiovascular, hepatic or renal diseases, or other diseases that might affect the study results or participants' safety as deemed by the investigator or designee.\n2. Participates with history of neuropsychiatric disorders, including current or past history of mental illness, current or recent use of psychotropic drugs, or other mental or psychological conditions deemed unsuitable for enrollment by the investigator or designee.\n3. Participates with abnormal blood pressure, such as systolic blood pressure ≥140 mmHg or \\\u003C90 mmHg; diastolic blood pressure ≥90 mmHg or \\\u003C60 mmHg.\n4. Participates with abnormal renal function, such as serum creatinine (Scr) \\> upper limit of normal (ULN), or estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin\u002F1.73m2 or ≥130 mL\u002Fmin\u002F1.73m2.\n5. Participates with history of severe drug or food allergies, or judged by the investigator to be potentially allergic to the investigational drug.\n6. Participates who have taken any prescription drugs, over-the-counter drugs, herbal medicines, vitamin\u002Fdietary supplements, or health products within 4 weeks before signing the ICF. Or those who are using long-acting oral contraceptives, long-acting contraceptive implants, or hormone-releasing intrauterine devices.\n7. Participates with history of diseases which could affect drug absorption, distribution, metabolism, or excretion (e.g., acute or chronic diarrhea or gastritis, gastrectomy, enterectomy, or cholecystectomy, etc., with the exception of appendectomy).\n8. Participates who have undergone any surgery within 6 months before signing the ICF, or those who plan to undergo surgery (including cosmetic surgery, dental operation, and oral surgery) during the study.\n9. Participates with QTcF interval \\>450 ms (males) or \\>470 ms (females), or those who have a history of QT interval prolongation.\n10. Participates who have experienced blood loss or blood donation exceeding 400 mL within 3 months before signing the ICF, or those who have received a blood transfusion or have used blood products.\n11. Regular alcohol consumption, defined as an average weekly alcohol intake \\>14 units of alcohol within the 3 months prior to signing the ICF (1 unit = 285 mL of beer, 25 mL of spirits or 150 mL of wine), or positive breath alcohol test, or unable to abstain from alcohol during the study.\n12. Participates who smoked ≥ 5 cigarettes per day within 6 months before signing the ICF, or who are unable to abstain from any tobacco products during the study.\n13. Participates with habitual excessive consumption of foods, fruits, or beverages containing purines, caffeine, or grapefruit and grapefruit juice, or other foods that may affect drug absorption, distribution, metabolism, or excretion, within 2 weeks before dosing, such as coffee (\\>1,100 mL\u002Fday), tea (\\>2,200 mL\u002Fday), cola (\\>2,200 mL\u002Fday), energy drinks (\\>1,100 mL\u002Fday) and chocolate (\\>510 g\u002Fday).\n14. Participates who have enrolled in any clinical studies of drug or medical device within 3 months before signing the ICF.\n15. Participates with history of drug abuse within 1 year before signing the ICF, or who have a positive drug test as screening.\n16. Female participates with a positive pregnancy test at screening or who is lactating.\n17. Participates who have positive results in one or more of the following examinations: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody, or anti-Treponema pallidum-specific antibody.\n18. Participates with history of needle or blood phobia, or those who have difficulty with venous blood collection or can't tolerate venipuncture for other reasons.\n19. Participates with special dietary requirements and cannot accept the standardized diet and schedule.\n20. Any other factors that the investigator deems unsuitable for participation in the study.",{"count":189,"type":23},72,[26],"This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK characteristics, and food effect of single ascending oral doses of SYH2056 tablets in healthy participants. The study is planned to have two Parts: Part 1 \\[the single ascending dose (SAD) study\\] and Part 2 (the food effect study).",[30],{"date":148,"type":40},{"date":195,"type":23},"2026-08-30",{"date":197,"type":23},"2027-03-30",{"name":199,"class":46},"InnovStone Therapeutics Limited",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":218,"locationsCount":47},"100652173","phase-1-study-to-assess-tolerability-of-injecting-larger-volumes-2-5-ml-subcutaneously-at-different-rates-participant-experience-and-acceptance-100652173","NCT07769489","Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance","An Exploratory Study to Investigate Pain Related to Injection of Large Volumes (up to 5mL) Subcutaneously","RISE","Inclusion criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Healthy male or female participants as judged by the investigator.\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Body Mass Index (BMI) greater than or equal to (\\>=) 18.5 and less than or equal to (\\\u003C=) 30.0 kilograms per square metre (kg\u002Fm\\^2) (both included).\n* White (Light skin that allows for adequate medical evaluation of any skin reactions).\n\nExclusion criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous randomisation in this study.\n* Previous rescreening for this study.\n* Pregnant or breastfeeding female participants.\n* Current participation (i.e., signed informed consent) in any other interventional clinical study. Treatment with an investigational medical product within 3 months or 5 half-lives (if known), whichever is longer prior to screening.\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol, including insufficient abdominal area for injection.\n* Intake of any medication that could influence pain perception or injection site reaction appearance (e.g., anti-coagulants, including low dose of aspirin, systemic antihistamines, pain-relieving, or anti-inflammatory medicinal products) within the last week before the intervention.\n* Intake of alcohol within the last 24 hours (self-reported) or a positive result of alcohol breath test prior to randomisation and intervention.\n* Intake of illicit drugs within the last 48 hours (self-reported) or a positive result of urine drug screening prior to screening.\n* Use of any nicotine products within the past month before screening.\n* Known active or inactive skin condition or disease, tattoos, or other interventions in the injection area that may affect pain perception or assessment of injection-site reactions.\n* Strenuous exercise within 3 days prior to the intervention.","64 Years",{"count":210,"type":23},100,[26],"The purpose of the study is to investigate the tolerability of different injection\u002Finfusion volumes and speed compared to standard practise. The order in which the different volumes and injection speeds will be given to participants will be allocated by chance. Participants will be in this clinical study for about 1 week.",[30],{"date":148,"type":40},{"date":174,"type":23},{"date":217,"type":23},"2026-12-11",{"name":219,"class":46},"Novo Nordisk A\u002FS",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100652620","phase-1-a-trial-of-lu-ah69593-in-healthy-participants-100652620","NCT07775261","A Trial of Lu AH69593 in Healthy Participants","Interventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4\u002F5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4\u002F5 Substrate in Healthy Participants","Key Inclusion Criteria:\n\n* The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, a neurological examination, vital signs, an electrocardiogram (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.\n* The participant is willing and able to attend trial appointments within the specified time windows.\n* The participant is willing to be an inpatient from the Baseline Visit to the Completion Visit.\n\nKey Exclusion Criteria:\n\n* The participant has taken any investigational medicinal product (IMP) \\\u003C2 months or \\\u003C5 halflives of that product, whichever is longer, prior to the first dose of IMP.\n* The participant has had, in the opinion of the investigator, a clinically significant illness from which he\u002Fshe recovered \\\u003C4 weeks prior to the first dose of IMP.\n* The participant has or has had, in the opinion of the investigator, any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.\n* For Part B only: the participant tests positive for HLA-B\\*15:02 or HLA-A\\*31:01 allele. 3.\n* For Part B only: the participant has a personal or family history of Stevens-Johnson syndrome or toxic epidermal necrolysis.\n\nAdditional protocol-defined criteria apply.",{"count":228,"type":23},46,[26],"This trial will evaluate the effects of itraconazole (Part A) and, carbamazepine (Part B) on Lu AH69593, and the effect of Lu AH69593 on midazolam (Part C) in adult healthy participants. The main goals of this trial are to learn about\n\n1. the effect of other medicines on Lu AH69593\n2. the pharmacokinetic parameters of Lu AH69593 (how the drug is absorbed, distributed, and processed by the body), and\n3. the safety and tolerability of Lu AH69593.",[30],"2026-08-13",{"date":77,"type":40},{"date":235,"type":23},"2026-08-27",{"date":237,"type":23},"2026-11-06",{"name":239,"class":46},"H. Lundbeck A\u002FS",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":24,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100652207","phase-1-a-phase-i-clinical-trial-to-evaluate-pharmacokinetics-of-hs-10504-100652207","NCT07770217","A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504","A Phase I Clinical Trial to Evaluate the Effect of Rifampin on the Pharmacokinetics of HS-10504 in Healthy Participants","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form prior to the study, fully understand the study content, procedures, and possible adverse events, and self-report the ability to complete the study in accordance with the protocol;\n2. Adult male and female participants (aged ≥18 years, calculated on the day of signing the informed consent form);\n3. Agree to pratice highly effective contraception from the signing of the informed consent form until 6 months after the last dose of HS-10504 and have no plans for reproduction or sperm\u002Fegg donation during this period.\n\nExclusion Criteria:\n\n1. Subjects with clinically significant abnormalities in physical examination, vital signs, 12-lead ECG, chest X-ray (posteroanterior and lateral views), clinical laboratory tests, etc., during the screening period, which are deemed unsuitable for enrollment by the investigator.\n2. Subjects with a history of severe diseases of the nervous, psychiatric, digestive, circulatory, respiratory, or urinary systems, or currently having such diseases, or newly diagnosed diseases before administration of the investigational product, which are assessed by the investigator as unsuitable for participation in this trial.\n3. Subjects who have had surgery within 3 months prior to screening, or have planned surgery during the trial, or have undergone surgery that may affect drug absorption, distribution, metabolism, or excretion, and are deemed unsuitable for enrollment by the investigator.\n4. Subjects who have participated in any other clinical trial and received any investigational drug\u002Fdevice within 3 months prior to screening.\n5. Subjects with a history of severe allergies, or allergic constitution, or known allergy to any component of the investigational product, or a history of hypersensitivity to drugs with chemical structures similar to HS-10504 or belonging to the same class as HS-10504.\n6. Subjects with a history of drug abuse, drug dependence, or illicit drug use within 5 years prior to screening, or those with a positive result in drug abuse screening.\n7. Subjects who are habitual drinkers within 3 months prior to screening, or those who cannot abstain from alcohol during the trial, or those with a positive breath alcohol test during screening.\n8. Subjects who have smoked an average of more than 5 cigarettes per day within 3 months prior to screening, or those who cannot refrain from using any tobacco products during the trial.\n9. Subjects who have consumed excessive amounts of tea, coffee, or caffeinated beverages within 3 months prior to screening.\n10. Subjects who have had significant blood loss (≥400 mL) or donated blood within 3 months prior to screening, or donated blood or lost blood ≥200 mL within 1 month, or those who plan to donate blood during the trial.\n11. Subjects who have used any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements (excluding topical agents with local effects) within 30 days prior to the first dose of the investigational product, or who have used any drug within a period less than 7 half-lives (whichever is longer) before dosing.\n12. Subjects who are lactating within 1 month prior to screening or during the trial, or female participants with a positive pregnancy test, or those who have had unprotected sexual intercourse within 14 days prior to screening.\n13. Subjects with special dietary requirements, unable to comply with the unified diet, or with dysphagia.\n14. Subjects who cannot tolerate venipuncture or indwelling needle blood sampling, or have a history of needle phobia or blood phobia.\n15. Subjects who may be unable to complete the trial for other reasons or are deemed unsuitable for participation by the investigator.",{"count":248,"type":23},18,[26],"This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.",[30],[253,254,255,256],"Phase I","Drug interaction","HS-10504","Healthy participants",{"date":148,"type":40},{"date":259,"type":23},"2026-08-02",{"date":261,"type":23},"2026-11-29",{"name":263,"class":46},"Jiangsu Hansoh Pharmaceutical Co., Ltd.",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":250,"conditions":274,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100651869","phase-1-a-phase-i-clinical-trial-to-evaluate-the-effect-of-itraconazole-on-the-pharmacokinetics-of-hs-10504-100651869","NCT07764692","A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504","A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504 in Healthy Participants","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form prior to the study, fully understand the study content, procedures, and possible adverse events, and self-report the ability to complete the study in accordance with the protocol;\n2. Adult male and female participants (aged ≥18 years, calculated on the day of signing the informed consent form);\n3. Agree to practice highly effective contraception from the signing of the informed consent form until 6 months after the last dose of HS-10504 and have no plans for reproduction or sperm\u002Fegg donation during this period.\n\nExclusion Criteria:\n\n1. Subjects with clinically significant abnormalities in physical examination, vital signs, 12-lead ECG, chest X-ray (posteroanterior and lateral views), clinical laboratory tests, abdominal and renal ultrasound, etc., during the screening period, which are deemed unsuitable for enrollment by the investigator.\n2. Subjects with a history of severe diseases of the nervous, psychiatric, digestive, circulatory, respiratory, or urinary systems, or currently having such diseases, or newly diagnosed diseases before administration of the investigational product, which are assessed by the investigator as unsuitable for participation in this trial.\n3. Subjects who have had surgery within 3 months prior to screening, or have planned surgery during the trial, or have undergone surgery that may affect drug absorption, distribution, metabolism, or excretion, and are deemed unsuitable for enrollment by the investigator.\n4. Subjects who have participated in any other clinical trial and received any investigational drug\u002Fdevice within 3 months prior to screening.\n5. Subjects with a history of severe allergies, or allergic constitution, or known allergy to any component of the investigational product, or a history of hypersensitivity to drugs with chemical structures similar to HS-10504 or belonging to the same class as HS-10504.\n6. Subjects with a history of drug abuse, drug dependence, or illicit drug use within 5 years prior to screening, or those with a positive result in drug abuse screening.\n7. Subjects who are habitual drinkers within 3 months prior to screening, or those who cannot abstain from alcohol during the trial, or those with a positive breath alcohol test during screening.\n8. Subjects who have smoked an average of more than 5 cigarettes per day within 3 months prior to screening, or those who cannot refrain from using any tobacco products during the trial.\n9. Subjects who have consumed excessive amounts of tea, coffee, or caffeinated beverages within 3 months prior to screening.\n10. Subjects who have had significant blood loss (≥400 mL) or donated blood within 3 months prior to screening, or donated blood or lost blood ≥200 mL within 1 month, or those who plan to donate blood during the trial.\n11. Subjects who have used any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements (excluding topical agents with local effects) within 30 days prior to the first dose of the investigational product, or who have used any drug within a period less than 7 half-lives (whichever is longer) before dosing.\n12. Subjects who are lactating within 1 month prior to screening or during the trial, or female participants with a positive pregnancy test, or those who have had unprotected sexual intercourse within 14 days prior to screening.\n13. Subjects with special dietary requirements, unable to comply with the unified diet, or with dysphagia.\n14. Subjects who cannot tolerate venipuncture or indwelling needle blood sampling, or have a history of needle phobia or blood phobia.\n15. Subjects who may be unable to complete the trial for other reasons or are deemed unsuitable for participation by the investigator.",{"count":272,"type":23},8,[26],[30],{"date":79,"type":40},{"date":277,"type":23},"2026-08-01",{"date":279,"type":23},"2027-03-31",{"name":263,"class":46},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":288,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":47},"100637968","phase-1-synaptic-mechanisms-of-intermittent-theta-burst-stimulation-for-major-depressive-disorder-100637968","NCT07593222","Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder","Inclusion Criteria:\n\n* Can safely receive TMS and study drugs\n* Stable medication regimen for one month prior to study participation, and for the duration of the study\n* Not currently receiving TMS, ECT, or ketamine\n* No active safety concerns related to suicidality\n\nExclusion Criteria:\n\n* History of seizures or epilepsy\n* History of intracranial pathology or lesions from any etiology\n* History of traumatic brain injury including prolonged loss of consciousness more than 15 min\n* Signs of increased intracranial pressure\n* Any major neurological conditions (ex: recent stroke, tumor, neurodegenerative disorders, etc.)\n* Major medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Severe migraines that may result in treatment intolerance.\n* Inability to tolerate MRI.\n* Pregnancy\n* Known allergic reaction to d-cycloserine or dextromenthorphan",{"count":210,"type":23},[26,289],"PHASE2","Many people with depression do not get better with standard treatments like medications or talk therapy. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment that uses magnetic pulses to stimulate areas of the brain involved in depression. One form of TMS called intermittent theta burst stimulation (iTBS) is FDA-cleared for depression and takes only 3 minutes to deliver. However, about one-third of patients do not respond to iTBS, and another one-third do not reach full remission. Improving iTBS requires a better understanding of how it works in the brain.\n\niTBS is thought to work by strengthening connections between brain cells, a process called synaptic plasticity. This process depends on a type of brain receptor called the NMDA receptor. Most of what researchers know about how iTBS affects these connections comes from studies of healthy people. It is not known whether iTBS works the same way in the prefrontal cortex - the brain region targeted during depression treatment - or in people who actually have depression.\n\nThis study has two phases.\n\nIn Phase 1, both healthy volunteers and people with depression will complete 4 research visits to test how iTBS changes brain activity in the prefrontal cortex and whether medications that increase or decrease NMDA receptor activity change those effects. Each visit involves active or sham (inactive) iTBS combined with one of three study medications: a placebo (inactive pill), d-cycloserine (a medication that increases NMDA receptor activity), or dextromethorphan (a medication that decreases NMDA receptor activity). Brain activity is measured before and after each TMS session using electroencephalography (EEG), a painless test that records electrical signals from the scalp through a cap placed on the head. All participants also complete a brain MRI before beginning study visits for targeting purposes.\n\nIn Phase 2, participants with depression will be offered a standard clinical course of 30 daily iTBS sessions (Monday through Friday over 6 weeks). Each session is combined with one blinded study medication (placebo, d-cycloserine, or dextromethorphan) taken daily. Brain activity measurements and standard depression and anxiety questionnaires are collected weekly throughout this phase to track how the brain changes over the course of treatment and whether those changes relate to improvements in symptoms.\n\nTogether, the two phases of this study aim to identify the brain mechanism by which iTBS works in people with depression. This knowledge could lead to more effective TMS treatments for people who have not responded to medications or other therapies.",[292,30],"Major Depression",[294,295,296,297,298],"TMS","depression","EEG","transcranial magnetic stimulation","pharmacologic augmentation","2026-08-12",{"date":79,"type":40},{"date":302,"type":23},"2026-09-01",{"date":304,"type":23},"2031-06-30",{"name":306,"class":84},"Mclean Hospital",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100651756","phase-1-clinical-trials-of-ibi3040-in-healthy-participants-and-overweight-or-obese-participants-100651756","NCT07765160","Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants","A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of a Single Subcutaneous Administration of IBI3040 in Healthy Participants and Multiple Subcutaneous Administrations in Overweight or Obese Participants","Inclusion Criteria:\n\nAll participants in Part A (SAD) and Part B (MAD) must meet inclusion criteria 1-3:\n\n* 1.The age at the time of informed consent should be between 18 and 65 years old (including both values), and there is no gender restriction.\n* 2.Female participants who are fertile and male participants whose partners are fertile must agree to use the contraceptive methods specified in the protocol during the study period and within 90 days after the last administration. The pregnancy test results of female participants with fertility before randomization must be negative. Female participants should not breastfeed. Male\u002Ffemale participants must be willing to avoid donating sperm\u002Feggs during the study period and within 90 days after the last administration.\n* 3\\. Be able to understand the procedures and methods of this research, be willing to strictly follow the clinical trial protocol to complete this trial, and voluntarily sign the informed consent form.\n\nParticipants of Part A (SAD) also need to meet inclusion criteria 4-6:\n\n* 4\\. Participants who were determined by the researchers to be normal or abnormal based on the results of various examinations such as medical history, vital signs, physical examination, 12-lead electrocardiogram, laboratory tests, infectious disease screening, chest X-ray, and abdominal color Doppler ultrasound, but were determined by the researchers to have no clinical significance.\n* 5\\. During screening, 20 kg\u002Fm ² ≤BMI \\\u003C28 kg\u002Fm ²;\n* 6\\. When screening, the standard weight should be ≥50 kg\n\nParticipants of Part B (MAD) also need to meet inclusion criteria 7-8:\n\n* 7\\. During screening, 24 kg\u002Fm2 ≤BMI ≤40 kg\u002Fm2;\n* 8\\. The standard weight change within 3 months prior to screening should be no more than 5kg (reported by the participants themselves).\n\nExclusion Criteria:\n\nAll participants in Part A (SAD) and Part B (MAD) who meet any one of the exclusion criteria 1-17 cannot be included in the corresponding stage of the study:\n\n* 1.Participants may be allergic to any component of the investigational drug, GLP-1 or Amylin receptor agonists (see Appendix 3 for details), or have used GLP-1 or Amylin receptor agonists within 3 months prior to screening;\n* 2\\. A history of diabetes, or a glycated hemoglobin level of ≥6.5% during the screening period, or a fasting blood glucose level of ≥7.0 mmol\u002FL;\n* 3\\. Previous history of thyroid C-cell carcinoma, multiple endocrine adenomatosis (MEN) 2A or 2B, or related family history, or calcitonin ≥20 ng\u002FL at screening;\n* 4\\. A history of acute or chronic pancreatitis in the past, or amylase or lipase \\>1.5× upper limit of the normal range (ULN) at the time of screening;\n* 5\\. Alanine aminotransferase \\>1.5×ULN during the screening period; Or aspartate aminotransferase \\>1.5×ULN; Or total bilirubin \\>1.5×ULN;\n* 6\\. During the screening period, the hepatitis B surface antigen is positive, or the hepatitis C antibody is positive, or the syphilis helix specific antibody is positive, or the HIV antibody is positive;\n* 7\\. Abnormal 12-lead electrocardiogram (ECG) during the screening period and judged by the researcher as having clinical significance, or ECG QTcF \\>450 ms, or heart rate \\\u003C60 beats per minute or \\>100 beats per minute;\n* 8\\. Having a history of suicidal behavior, or being considered to have a significant suicide risk at present, or having a PHQ (Depression Screening Scale) score of ≥15 at the time of screening, or being classified as category 4 or 5 on the C-SSRS (Columbia Suicide Severity Scale) at the time of screening, or choosing \"yes\" in suicidal behavior or suicidal ideation;\n* 9\\. Use of prescription and over-the-counter drugs within 2 weeks before screening or within 5 half-lives (excluding topical eye\u002Fnasal drops and creams without systemic exposure risk);\n* 10\\. Have participated in any clinical trials of drugs (or within five half-lives) or medical devices within three months prior to screening, or plan to participate in clinical trials of other drugs or medical devices during the trial period;\n* 11\\. Those who consumed an average of more than 2 units of alcohol per day in the three months prior to screening (1 unit of alcohol ≈360 mL of beer with an alcohol content of 5% or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine with an alcohol content of 12%), or those who were unable to quit drinking during the trial period, or those with a positive breath test for alcohol;\n* 12\\. Smoking more than 5 cigarettes per day within the 3 months prior to screening;\n* 13\\. Those who have a history of drug abuse within the five years prior to screening, or have used drugs within the three months prior to screening, or have a positive urine drug screening result;\n* 14\\. Blood donation and\u002For blood loss within 3 months prior to screening ≥450 mL, or having undergone bone marrow donation, blood transfusion or severe blood loss, or having hemoglobinopathy, hemolytic anemia, sickle cell anemia, or hemoglobin \\\u003C120 g\u002FL (for men) or \\\u003C110 g\u002FL (for women);\n* 15\\. Inability to tolerate venipuncture for blood collection or fainting at the sight of needles and blood;\n* 16\\. Those whose injection site assessment is considered abnormal by the researchers;\n* 17\\. The researcher believes that there are other factors that are not suitable for participating in this trial.\n\nParticipants in Part A (SAD) cannot be included in the study if they meet the following exclusion criteria:\n\n\\- 18. During the screening period, the systolic blood pressure is less than 90mmHg or ≥140mmHg, or the diastolic blood pressure is less than 50 mmHg or ≥90mmHg, or the pulse rate is less than 60 beats per minute or \\>100 beats per minute.\n\nParticipants in Part B (MAD) who meet any one of the exclusion criteria 19-25 cannot be included in the study:\n\n* 19\\. The following diseases (including but not limited to gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases) with clinical findings indicating clinical significance within 12 months prior to screening;\n* 20\\. A history of life-threatening diseases (excluding basal cell skin cancer or squamous cell skin cancer) within the five years prior to screening;\n* 21\\. Previous researchers have considered clinically significant gastric emptying abnormalities (for example, severe gastroparesis or gastric outlet obstruction), who have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery, or have been taking drugs that directly affect gastrointestinal motility for a long time;\n* 22\\. During the screening period, systolic blood pressure is less than 90 mmHg or ≥160mmHg, or diastolic blood pressure is less than 50 mmHg or ≥100mmHg, or pulse rate is less than 60 beats per minute or \\>100 beats per minute.\n* 23\\. For drugs that have been used or are currently being used within the three months prior to screening and may cause significant standard weight gain, including but not limited to: tricyclic antidepressants, psychotropic drugs or sedatives (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenylhydrazine, chlorpromazine, thiridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);\n* 24\\. Having used weight-loss drugs or alternative therapies within the three months prior to screening, including but not limited to: GLP-1 or Amylin receptor agonists, orlistat, sibutramine hydrochloride, phenylpropanolamine, chlorphenimidole, butylamine, clocaserin hydrochloride, fentamine, fentamine\u002Ftopiramate mixture, anferylene and naltrexone\u002Fbupropion mixture.\n* 25\\. Thyroid tumors or thyroid nodules with a Thyroid Imaging Reporting and Data System (TI-RADS) grade of ≥4 were present during screening.",{"count":315,"type":23},96,[26],"Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.",[30,319],"Overweight or Obese Participants","2026-08-11",{"date":79,"type":40},{"date":195,"type":23},{"date":324,"type":23},"2027-12-10",{"name":326,"class":46},"Innovent Biologics (Suzhou) Co. Ltd.",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":47},"100651132","phase-1-evaluation-of-bioequivalence-and-food-effect-of-a-new-strength-formulation-of-ammoxetine-hydrochloride-enteric-coated-tablets-in-healthy-participants-100651132","NCT07756996","Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.","Inclusion Criteria:\n\n1. Adults aged 18 \\~65 years (inclusive), male or female;\n2. Body weight ≥ 45.0 kg (female) or ≥ 50.0 kg (male), body mass index (BMI) in the range of 19.0 \\~ 28.0 kg\u002Fm2 (inclusive);\n3. Participants with normal results or abnormal results without clinical significance in medical history, vital signs, physical examination, laboratory tests (including hematology, blood biochemistry, urinalysis, coagulation function, and related tests), chest X-ray, and other examinations.\n4. Participants and their partners must use effective non-hormonal contraceptive measures (e.g., condoms, inert intrauterine devices, etc.) from 2 weeks before screening until 6 months after the end of the study, unless they have already undergone permanent sterilization (e.g., bilateral tubal ligation, vasectomy, etc.). Participants must also refrain from donating sperm or eggs;\n5. Participants who voluntarily sign the informed consent form and are willing to comply with the protocol to complete the study.\n\nExclusion Criteria:\n\n1. Participants with a history of allergic constitution (allergic to two or more drugs, foods, or pollens);\n2. Participants with psychiatric disorders, hepatic or renal dysfunction, gastrointestinal disorders, neurological disorders, or other systemic diseases;\n3. Participants with orthostatic hypotension (a decrease in systolic blood pressure of ≥20 mmHg or diastolic blood pressure of ≥10 mmHg upon standing compared to the supine position);\n4. Participants with a QTcF interval exceeding the upper limit of normal (males \\>450 ms or females \\>470 ms) on 12-lead ECG, or clinically significant abnormalities on a ECG as judged by the investigator, or a history of arrhythmia, syncope associated with arrhythmia, use of a cardiac pacemaker, or other cardiac conditions. Note: Cardiac conditions include, but are not limited to: heart failure; hypokalemia; atrial fibrillation, atrial flutter, atrial premature beats, ventricular premature beats, non-sustained or sustained ventricular tachycardia; bradycardia or sick sinus syndrome; personal or family history of any cardiac conduction abnormalities; personal or family history of long QT syndrome (LQTS); or family history of sudden cardiac death;\n5. Heavy smokers or heavy drinkers (consumption of 14 units of alcohol per week within 4 weeks prior to screening: 1 unit = 285 mL beer, or 25 mL spirits, or 150 mL wine; smoking ≥5 cigarettes per day) or those with a history of other substance or drug abuse within the past year;\n6. Participants with a positive alcohol breath test or positive urine drug screen at screening;\n7. Participants with blood donation or blood loss exceeding 200 mL within 8 weeks prior to screening;\n8. Participants who have participated in another clinical trial of an investigational drug within 3 months prior to screening;\n9. Participants who habitually consumed excessive caffeinated beverages or foods within 4 weeks prior to screening (e.g., coffee, tea, chocolate, cola, energy drinks) with a daily caffeine intake exceeding 6 units. (1 caffeine unit = 1 cup of coffee \\[177.4 mL\\] = 2 cans of cola \\[354.9 mL\\] = 1 cup of tea \\[354.9 mL\\] = 1\u002F2 can of energy drink = 85 g of chocolate);\n10. Participants who used strong or moderate inhibitors of the drug-metabolizing enzyme (CYP2D6) within 4 weeks prior to screening\n11. Participants who habitually consumed dragon fruit, mango, grapefruit, pomelo, sour orange, starfruit, pomegranate, or food\u002Fbeverages prepared from these fruits within 7 days prior to screening;\n12. Participants who used prescription drugs, over-the-counter drugs, herbal products, vitamins, or minerals within 2 weeks prior to screening, or failed to complete at least 5 half-lives of elimination for previously used drugs, whichever is longer;\n13. Participants who used any psychotropic drugs or psychoactive substances within 1 year prior to screening (psychoactive substances include central nervous system depressants, stimulants, hallucinogens, opioids, volatile solvents, novel psychoactive substances, etc.);\n14. Pregnant or lactating women, or female participants with a positive pregnancy test at screening;\n15. Participants with a history of surgery that affects the in vivo disposition of drugs, or any surgery within 3 months prior to screening, or planned surgery during the study period;\n16. Participants who have hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption (history of diarrhea after drinking milk);\n17. Participants with any other condition deemed by the investigator as unsuitable for participation in this study, or withdrawal of consent for personal reasons.",{"count":334,"type":23},62,[26],"Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine hydrochloride Enteric-coated Tablets in Healthy Participants.The study is composed of 2 parts. Part 1 is a bioequivalence study with administration 1.5 hours after a high-fat meal, using a randomized, open-label, single-dose, four-period fully replicated design. Part 2 is a food effect study using a single-center, open-label, single-dose, two-period crossover design.",[30],"2026-08-10",{"date":320,"type":40},{"date":341,"type":40},"2026-07-15",{"date":343,"type":23},"2026-10-31",{"name":345,"class":46},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":369},"100632247","a-study-to-investigate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-azd1043-in-healthy-adult-participants-living-with-overweight-andor-obesity-100632247","NCT07511205","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and\u002For Obesity.","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and\u002For Intravenous Administration in Healthy Adult Participants Living With Overweight and\u002For Obesity.","Inclusion Criteria:\n\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n* Have a body mass index between 25 and 39.9 kg\u002Fm2 (Global cohorts \\[Parts A1 and B1\\]), or 23 and 39.9 kg\u002Fm2 (Japanese \\[Parts A2 and B2\\] and Chinese \\[Part A3\\] cohorts) inclusive and weigh at least 50 kg.\n* For the Parts A2 and B2, participants should be Japanese (natives of Japan or Japanese Americans), having both parents and 4 grandparents who are Japanese. This includes healthy second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.\n* For the Part A3, participants should be Chinese defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity to drugs of a similar class to AZD1043.\n* Has received prescription, non-prescription, or experimental medications for weight loss within 3 months prior to the Screening Visit.\n* History of psychosis or bipolar disorder or major depressive disorder within the past 2 years with the participant being clinically unstable.",{"count":354,"type":23},104,[26],"The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and\u002For obesity, including participants of Japanese and Chinese descent.",[30,170],[359,360,361,104,362],"First time in human","Single ascending dose","Multiple ascending dose","Pharmacodynamics",{"date":338,"type":40},{"date":365,"type":40},"2026-03-30",{"date":367,"type":23},"2027-11-17",{"name":114,"class":46},3,{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":377,"targetDuration":4,"studyType":24,"phases":379,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":47},"100637630","a-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-enicepatide-in-generally-healthy-adult-chinese-participants-100637630","NCT07626515","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants","A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg\u002Fm2","Inclusion Criteria:\n\n* No evidence of active or chronic disease as determined by detailed medical and surgical history and the results of a physical examination, vital signs, 12 lead electrocardiogram (ECG), or clinical laboratory tests\n* BMI ≥23 kg\u002Fm\\^2 at screening\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of acute or chronic pancreatitis\n* History of clinically significant gallbladder disease in the opinion of the investigator\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* History or presence of an abnormal ECG that is deemed clinically significant in the opinion of the investigator\n* Clinically significant abnormalities (as judged by the investigator) in laboratory test results\n* History or presence of clinically significant cardiovascular disease, renal disease, hepatic disease, gastrointestinal disease, hematological disease, immunological disease, neurological disease, endocrine disease, metabolic disease, pulmonary disease, or history of any of these diseases with renal, hepatic, or cardiopulmonary dysfunction",{"count":378,"type":23},36,[26],"This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg\u002Fm\\^2).",[30],"2026-08-06",{"date":338,"type":40},{"date":385,"type":40},"2026-07-02",{"date":387,"type":23},"2027-05-14",{"name":389,"class":46},"Hoffmann-La Roche",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":47},"100631253","location--and-frequency-dependent-effects-of-thalamic-temporal-interference-stimulation-during-sleep-100631253","NCT07498270","Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep","CAP-TI","Inclusion Criteria:\n\n* Medically healthy (based on self-report and study team review)\n* U.S. citizen or holding permanent resident status\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepine, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); OTC antihistamines (diphenhydramine, Benadryl)\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)","40 Years",{"count":399,"type":23},24,[61],"This study is to find out whether a type of non-invasive electrical brain stimulation called temporal interference transcranial electrical stimulation (TI-TES) can temporarily change brain activity during sleep, especially sleep spindles (brain rhythms in the \\~8-16 Hz range). Up to 24 healthy participants in Dane County, Wisconsin will be enrolled for 3 overnight study visits. Participants can expect to be on study for approximately 5 weeks, depending on scheduling availability.",[67,30],[404,405,406,407,408,409,410,411],"sleep","spindles","non-rapid eye movement","SSD","neurobiology","impairment","brain stimulation","non-invasive stimulation",{"date":338,"type":40},{"date":414,"type":40},"2026-06-05",{"date":416,"type":23},"2028-02",{"name":418,"class":84},"University of Wisconsin, Madison",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":47},"100609833","temporal-interference-for-thalamocortical-activity-and-network-modulation-100609833","NCT07219719","Temporal Interference for Thalamocortical Activity and Network Modulation","TITAN","Inclusion Criteria:\n\n* Adults aged 18-50\n* Medically healthy\n* U.S. citizen or holding permanent resident status\n* English-speaking\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., Attention-deficit\u002Fhyperactivity disorder (ADHD) stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepin, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); over the counter antihistamines (diphenhydramine, Benadryl); Estradiol-based birth control\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)","50 Years",{"count":428,"type":23},40,[26],"The goal of this clinical trial is to find out whether a type of electrical brain stimulation, called temporal interference stimulation, can temporarily change the way different parts of the brain communicate with each other.\n\nParticipants will:\n\n* Complete two stimulation phases - overnight and during wakefulness\n* Undergo two MRIs per study phase",[30],{"date":338,"type":40},{"date":434,"type":40},"2025-12-01",{"date":436,"type":23},"2027-11",{"name":418,"class":84},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":446,"targetDuration":4,"studyType":24,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":463,"locationsCount":4},"100650380","phase-1-a-study-of-byn-001-in-healthy-adults-and-in-adults-with-moderate-to-severe-atopic-dermatitis-100650380","NCT07746817","A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis","A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BYN-001 in Healthy Adult Participants and Participants With Moderate to Severe Atopic Dermatitis","BYN-001-101","Part A and B Key Inclusion Criteria:\n\n* Age 18-55 years of age\n* Must be in good health with no significant medical conditions\n* Willing and able to attend all study visits and comply with study requirements\n* Able and willing to provide written informed consent\n\nPart A and B Exclusion Criteria:\n\n* Evidence of clinically significant condition or disease\n* Any physical or psychosocial condition that prohibits study completion\n* Know history of illicit drug use or abuse, alcoholism and\u002For smoking more than -5 cigarettes a day in the prior 3 months\n* History of sever allergic reactions of hypersensitivity\n\nPart C Inclusion Criteria\n\n* Age 18-55 years of age\n* Must be in good health with no significant medical conditions\n* Willing and able to attend all study visits and comply with study requirements\n* Able and willing to provide written informed consent\n* Documented chromic atopic dermatitis within 1 year prior to screening\n* Moderate to severe atopic dermatitis\n\nPart C Key Exclusion Criteria\n\n* Evidence of clinically significant condition or disease\n* Any physical or psychosocial condition that prohibits study completion\n* Know history of illicit drug use or abuse, alcoholism and\u002For smoking more than 5 cigarettes a day in the prior 3 months\n* History of sever allergic reactions of hypersensitivity\n* Incomplete washout of prior atopic dermatitis medications\n* Other confounding skin diseases",{"count":447,"type":23},56,[26],"This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis. Parts A and B are randomized, double-blind, placebo-controlled single and multiple ascending dose cohorts in healthy adults, that will assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of BYN-001. Part C will assess BYN-001 in adults with moderate to severe atopic dermatitis.",[451,30],"Atopic Dermatitis",[453,454,455,361,360,456,457],"IL-25","Monoclonal antibody","First-in-human","Atopic dermatitis","Healthy Participant","2026-08-05",{"date":151,"type":40},{"date":277,"type":23},{"date":462,"type":23},"2028-12-31",{"name":464,"class":46},"Bionyra Pharma",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":47},"100650883","phase-1-phase-1-study-in-healthy-adults-to-see-how-sevabertinib-changes-metformin-levels-in-the-body-100650883","NCT07753252","Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body","Phase 1, Open-label, Fixed-sequence Crossover Study to Investigate the Effect of Sevabertinib on the Pharmacokinetics of Metformin in Healthy Participants","Inclusion:\n\n* Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.\n* Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, physical examination, 12-lead ECG, and clinical laboratory tests.\n* Participant is a non-smoker who has not used tobacco- or nicotine-containing products for at least 6 months before the first study intervention administration.\n* Body mass index (BMI) within the range 18.5 to 30.0 kg\u002Fm² (inclusive) and a body weight of at least 50 kg at screening.\n* Female, of non-childbearing potential only (see Section 10.4.1). Females must not be pregnant or breastfeeding, and must be documented as of non-childbearing potential (WONCBP). A negative pregnancy test is required\n\nExclusion:\n\n* Existing relevant diseases of vital organs (e.g., cardiovascular, liver, gastrointestinal, renal, respiratory, or central nervous system diseases) or other organs (e.g., diabetes mellitus).\n* Known history of hypersensitivity to sevabertinib, metformin, or any of their excipients.\n* History of known or suspected malignant tumors.\n* Regular use of medicines within 4 weeks prior to screening.\n* Administration of strong or moderate inhibitors or inducers of CYP3A4, P-gp, MATE1\u002F2-K, or OCT2 within 4 weeks or 5 half-lives prior to the first study intervention administration, whichever is longer.\n* Use of any prescription drug or over-the-counter (OTC) medication within 2 weeks or 5 half-lives of the prescription medication prior to the first study intervention administration (whichever is longer), except for occasional use of acetaminophen (up to 2 g\u002Fday) within 7 days prior to the first study intervention administration.\n* Use of supplements or herbal remedies within 2 weeks prior to the first study intervention administration, except for vitamins.\n* Excessive intake of methylxanthine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the investigator. Excessive intake of methylxanthine is defined as the regular consumption of more than 600 mg of caffeine per day (e.g., \\>5 cups of coffee) or would likely be unable to refrain from the use of methylxanthine-containing beverages and food during confinement at the clinic.\n* Clinically relevant findings in the ECG such as a second- or third-degree atrio-ventricular block, prolongation of the average QRS complex over 120 msec or of the QTc (Fridericia correction) interval over 450 msec or any other finding which in the opinion of the investigator will hinder participant's safety at screening or check-in (Day-1).\n* Positive results for hepatitis B virus surface antigen, hepatitis B virus core antibody, hepatitis C virus antibodies, human immunodeficiency virus antibodies 1 and\u002For 2 at screening.\n* Estimated creatinine clearance \\\u003C90 mL\u002Fmin according to Cockcroft-Gault formula (at screening).\n* Positive urine drug and cotinine screening at screening or check-in (Day-1).\n* Positive urine alcohol test at screening or check-in (Day-1).\n* Unable\u002Funwilling to comply with study restrictions.",{"count":428,"type":23},[26],"This Phase 1 study in healthy adults looks at whether sevabertinib changes how the body handles metformin. The study is based on the idea that sevabertinib may block kidney transporters (proteins that move medicines) called MATE1 and MATE2-K, which help remove metformin from the body. Each participant receives a single dose of metformin alone, and later receives sevabertinib for several days and then takes metformin again while still taking sevabertinib. The study aims to learn how metformin, gets into, moves through, and out of the body when it is administered with sevabertinib. This is called \"Pharmacokinetics\". Furthermore, the study will help us learn about the safety and tolerability of sevabertinib and metformin when given alone or in combination.",[30],"2026-08-04",{"date":151,"type":40},{"date":39,"type":23},{"date":480,"type":23},"2026-09-28",{"name":482,"class":46},"Bayer",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":24,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":4},"100650770","phase-1-comparative-pk-assessment-study-of-casdatifan-in-moderate-hepatically-impaired-participants-versus-matched-participants-with-normal-hepatic-function-100650770","NCT07751250","Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function","A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of Casdatifan (AB521) in Participants With Moderate Hepatic Impairment Compared to Healthy Matched Participants","Inclusion Criteria:\n\nAll Participants:\n\n* Male participants must be vasectomized\n* BMI ≥ 18.0 and ≤ 42.0 kg\u002Fm2 and body weight ≥ 45 kg at screening.\n\nParticipants with Moderate HI (Group 1)\n\n* Is classified as having moderate HI by the Child-Pugh classification system (Class B, score of 7 to 9, inclusive) at screening.\n* Has a diagnosis of chronic (\\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency at screening\n\nHealthy Participants:\n\n* Healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee\n\nExclusion Criteria:\n\nAll Participants:\n\n* Participants with Gilbert's syndrome.\n\nParticipants with Moderate HI (Group 1):\n\n* Positive for HBsAg or HCV Ab, and detectable viral load at screening.\n* Severe complications of liver disease within the preceding 3 months of screening.\n* Fluctuating or rapidly deteriorating hepatic function from screening until prior to dosing, in the opinion of the PI or designee.\n\nHealthy Control Participants:\n\n* History or presence of clinically significant medical or psychiatric condition or disease, or presence of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","84 Years",{"count":492,"type":23},16,[26],"The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.",[30,496],"Hepatic Impairment",[498,499,500,104,496],"Casdatifan","AB521","HIF-2α","2026-08-03",{"date":151,"type":40},{"date":504,"type":23},"2026-08",{"date":506,"type":23},"2027-05",{"name":508,"class":46},"Arcus Biosciences, Inc.",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":519,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":47},"100650253","pupillary-dilation-reflex-in-healthy-volunteers-100650253","NCT07746167","Pupillary Dilation Reflex in Healthy Volunteers","The Relationship Between Neurostimulation Intensity and Pupillary Dilation Reflex (PRD) in Healthy Volunteers","Inclusion Criteria:\n\n* Age 18-60 years.\n* In good general health (self-reported).\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Eye pathology that prevents accurate pupillometry.\n* Pregnancy (Self-Report)\n* Diagnosis of autoimmune disorders.\n* Diagnosis of any neuropathic disorder\n* Inability to complete questionnaires.","60 Years",{"count":518,"type":23},60,"OBSERVATIONAL","This a single site, observational study that will examine how the pupil responds to neurostimulation under different conditions in healthy adults. The objective is to measure pupillary dilation reflex (PRD) in response to increasing neurostimulation intensities using the AlgometRx device.",[30],"2026-07-30",{"date":476,"type":40},{"date":525,"type":40},"2026-04-29",{"date":527,"type":23},"2027-06",{"name":529,"class":84},"Children's National Research Institute",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":516,"enrollmentInfo":537,"targetDuration":4,"studyType":24,"phases":539,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":550,"locationsCount":47},"100650205","phase-1-a-phase-1-trial-of-amg-691-in-healthy-chinese-and-japanese-volunteers-100650205","NCT07745907","A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers","A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 691 Administered in Healthy Chinese and Japanese Participants","Inclusion Criteria:\n\n* Healthy male or female participants, 18 to 60 years of age.\n* First-generation Chinese ancestry (born in China, Hong Kong, Taiwan, or Macau with 2 Chinese parents and 4 Chinese grandparents) or first-generation Japanese ancestry (born in Japan with 2 Japanese parents and 4 Japanese grandparents).\n* Body mass index (BMI) 18.0 to 30.0 kg\u002Fm\\^2 (inclusive) and body weight ≥40 kg.\n* In good general health based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations.\n* Female participants must not be pregnant or breastfeeding.\n* Participants of reproductive potential must agree to follow protocol-specified contraception requirements.\n* Willing to maintain usual diet and physical activity regimen throughout study participation.\n\nExclusion Criteria:\n\n* Clinically significant medical condition, disease, or abnormal finding that could interfere with study participation or interpretation of results.\n* Clinically significant ECG abnormalities\n* Clinically significant abnormal blood pressure or pulse rate at screening\u002Fcheck-in.\n* History of malignancy (except adequately treated in situ cervical cancer or non-melanoma skin cancer \\>5 years before dosing).\n* Deep vein thrombosis or pulmonary embolism within 3 months prior to check-in.\n* History of hypersensitivity\u002Fanaphylaxis to biologic therapies, mammalian-derived products, or AMG 691 excipients.\n* Active, chronic, recurrent, or unresolved infection; history of severe infection requiring intravenous (IV) antibiotics within the past 3 years.\n* Positive or indeterminate QuantiFERON-TB Gold test.\n* Untreated or unresolved helminth parasitic infection.\n* History of immunodeficiency.\n* Receipt of live or live-attenuated vaccines within 12 weeks before check-in or planned during the study.\n* Estimated glomerular filtration rate (eGFR) \\\u003C70 mL\u002Fmin\u002F1.73 m\\^2.\n* Alanine Aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, or direct bilirubin \\>1.5 × Upper Limit Normal (ULN).\n* Positive screening tests for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection.\n* Use of prohibited prescription, over-the-counter, herbal, vitamin, or dietary supplement products within 30 days (or 5 half-lives) before enrollment, unless approved by the investigator.\n* History of illicit drug use within 1 year, positive drug screen, or unwillingness to abstain from illicit drugs\u002Fcannabinoids during the study.\n* Use of tobacco or nicotine-containing products within 6 months prior to check-in.\n* History of alcohol abuse or excessive alcohol consumption.\n* History of non-suicidal self-injury within 5 years or unstable major depressive disorder\u002Fother severe psychiatric disorder within 2 years.\n* Participation in another investigational drug study within 90 days (or 5 half-lives) prior to check-in.\n* Previous exposure to AMG 691.\n* Recent donation of blood, plasma, or platelets.\n* Any participant considered unsuitable by the investigator or unwilling to comply with study restrictions.",{"count":538,"type":23},28,[26],"The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants",[30],[543,544,545,546],"AMG 691","Respiratory Tract Diseases","Asthma","Lung Diseases",{"date":476,"type":40},{"date":151,"type":23},{"date":279,"type":23},{"name":551,"class":46},"Amgen",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":115},"100615259","phase-1-a-study-to-investigate-safety-tolerability-and-pharmacokinetics-of-azd3974-in-healthy-participants-100615259","NCT07290283","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD3974 After Single and Multiple Ascending Dosing to Healthy Participants","Inclusion Criteria:\n\n* Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit.\n* All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopausal status or documentation of irreversible surgical sterilization at the Screening Visit.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.\n* Have a body mass index between 18 and 32 kg\u002Fm2 inclusive and weigh at least 50 kg at Screening.\n* For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese (eg, natives of Japan or Japan Americans), defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.\n* For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and 4 grandparents are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.\n* Any positive result on Screening for serum hepatitis B and C viruses and human immunodeficiency virus.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiography at Screening and\u002For admission to the Clinical Unit .\n* Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.\n* Positive screen for drugs of abuse, or alcohol, or cotinine.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity.\n* Participants who have previously received AZD3974.",{"count":560,"type":23},176,[26],"The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.",[30],[360,361,104,565,455],"Impact of food",{"date":567,"type":40},"2026-07-31",{"date":569,"type":40},"2025-12-10",{"date":571,"type":23},"2026-10-21",{"name":114,"class":46},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":17,"sex":18,"minAge":580,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":519,"phases":4,"briefSummary":583,"conditions":584,"keywords":594,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":606},"100137498","natural-history-study-of-and-genetic-modifiers-in-spinocerebellar-ataxias-100137498","NCT01060371","Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias","Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA) for the Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)","Inclusion Criteria:\n\n* Affected individuals aged 6 or above with symptoms and\u002For signs of ataxia with genetic confirmation of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia either in themselves or first degree family member.\n* Any individual aged 18 or above with a definite molecular diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia.\n* Former participants of the READISCA (NCT03487367) study.\n* Willingness to participate in the study and ability to give informed consent\n* For MRI Sub-Study only: Previous READISCA enrollees; individuals aged 18 or above with a genetic confirmation of SCA1, 2, or 3 and a SARA score \\\u003C10 at MRI pre-screening; Healthy control participants without neurological condition.\n\nExclusion Criteria:\n\n* Exclusion of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia by previous DNA testing.\n* A lack of willingness to participate in the study\n* For MRI Sub-study only: Inability to undergo MRI scanning, pregnancy, and other neurological diseases than those of interest.","6 Years",{"count":582,"type":23},1400,"Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCAs and this study will focus on types 1, 2, 3, 6, 7, 8, 10, 27B, and RFC1-ataxia (SCA 1, SCA 2, SCA 3, also known as Machado-Joseph disease, SCA 6, SCA 7, SCA 8, SCA 10, SCA27B, and RFC1-ataxia, also known as CANVAS). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties, and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease.\n\nThe research questions are:\n\n1. How do these diseases progress over time?\n2. What are the best ways to measure the progression?\n3. Do some genes, other than the gene that is abnormal in these diseases, have any effect on the way the disease behaves?\n\nThis is a nationwide study and the investigators expect that 1400 patients will participate all over North America. The participants will remain in the study for an indeterminate period of time, for as long as they are willing to participate. Study visits will be done every 12 months.\n\nWithin the broader CRC-SCA, there is an Imaging Sub-study aiming to identify magnetic resonance imaging (MRI) markers sensitive to the onset and progression of common SCAs. To accomplish this, participants attend annual visits involving a neurological exam, surveys, a blood draw, and an MRI scan. Participants can attend visits at one of three US locations - Minneapolis, MN; Gainesville, FL; or Dallas, TX and two European locations - Paris, France and Bonn, Germany. Eligible participants must either have SCA1, 2, or 3 or have been a participant of the previous READISCA study (NCT03487367). Gene-positive participants must have a SARA score less than 10; however, there is no SARA limit for participants previously enrolled in READISCA. All participants must be 18 years or older. Gene-negative participants should be 25-65 years old.",[585,586,587,588,589,590,591,592,593,30],"Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 10","RFC1 Gene Mutation","Spinocerebellar Ataxia Type 27b",[595,596,597,598],"Spinocerebellar Ataxia","Natural History","Genetic Modifiers","Biomarkers",{"date":501,"type":40},{"date":601,"type":40},"2010-04",{"date":603,"type":23},"2030-12",{"name":605,"class":84},"Lauren Moore",17]